BH3 peptides and methods of use thereof
View Patent ↗The invention provides peptides and the nucleic acid sequences that encode them. The invention further provides therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of apoptosis associated disorders.
1. A composition for detecting homo-oligomerization of a BAX or BAK protein in a mitochondrial membrane, comprising: a synthetic or recombinant BAD-like BH3 domain peptide comprising SEQ ID NO: 6 or SEQ ID NO: 7 that binds MCL-1 and consists of a peptide of less than or equal to 50 amino acids in length; and a mitochondrion comprising an MCL-1 protein in a complex with a BID peptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 1 or a BIM peptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 2, wherein the BID or BIM peptide activates pro-apoptotic BAX or BAK when displaced from the complex by the BAD-like BH3 domain peptide to thereby induce homo-oligomerization of the BAX or BAK protein in the mitochondrial membrane.
2. The composition of claim 1 , wherein the BAD-like BH3 domain peptide preferentially binds to an anti-apoptotic BCL-2 family protein over a pro-apoptotic BCL-2 family protein.
3. The composition of claim 2 , wherein the anti-apoptotic BCL-2 family protein is MCL-1.
4. The composition of claim 2 , wherein the pro-apoptotic BCL-2 family protein is BAX or BAK.
5. The composition of claim 1 , wherein the BH3 domain peptide comprises SEQ ID NO: 6.
6. The composition of claim 1 , wherein the BH3 domain peptide comprises SEQ ID NO: 7.
7. The composition of claim 1 , wherein the mitochondrion is isolated from a cell.
8. The composition of claim 1 , wherein the BID peptide consists of the amino acid sequence of SEQ ID NO: 1.
9. The composition of claim 1 , wherein the BIM peptide consists of the amino acid sequence of SEQ ID NO: 2.
10. A composition for detecting homo-oligomerization of a BAX or BAK protein in a mitochondrial membrane, comprising: a mitochondrion contacted with a synthetic or recombinant BAD-like BH3 domain peptide comprising SEQ ID NO: 6 or SEQ ID NO: 7 that binds MCL-1 and consists of a peptide of less than or equal to 50 amino acids in length; and a BID peptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 1 or a BIM peptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 2 in a complex with an MCL-1 protein resident on the mitochondrion, wherein the BID or BIM peptide activates pro-apoptotic BAX or BAK when displaced from the complex by the BAD-like BH3 domain peptide to thereby induce homo-oligomerization of the BAX or BAK protein in the mitochondria.
11. The composition of claim 10 , wherein the BAD-like BH3 domain peptide preferentially binds to an anti-apoptotic BCL-2 family protein over a pro-apoptotic BCL-2 family protein.
12. The composition of claim 11 , wherein the anti-apoptotic BCL-2 family protein is MCL-1.
13. The composition of claim 11 , wherein the pro-apoptotic BCL-2 family protein is BAX or BAK.
14. The composition of claim 10 , wherein the BH3 domain peptide comprises SEQ ID NO: 6.
15. The composition of claim 10 , wherein the BH3 domain peptide comprises SEQ ID NO: 7.
16. The composition of claim 10 , wherein the mitochondrion is isolated from a cell.
17. The composition of claim 10 , wherein the BID peptide consists of the amino acid sequence of SEQ ID NO: 1.
18. The composition of claim 10 , wherein the BIM peptide consists of the amino acid sequence of SEQ ID NO: 2.